A Perspective to the Correlation Between Brain Insulin Resistance and Alzheimer: Medicinal Chemistry Approach

Author(s): Navid Rabiee , Mojtaba Bagherzadeh , Mohammad Rabiee* .

Journal Name: Current Diabetes Reviews

Volume 15 , Issue 4 , 2019

Become EABM
Become Reviewer

Abstract:

Substantial terms have been recognized on the associated risk elements, comorbidities as well as, putative pathophysiological processes of Alzheimer disease and related dementias (ADRDs) as well as, type 2 diabetes mellitus (T2DM), a few from greatest important disease from the moments. Very much is considered regarding the biology and chemistry of each predicament, nevertheless T2DM and ADRDs are an actually similar pattern developing from the similar origins of maturing or synergistic conditions connected by aggressive patho-corporeal terms and continues to be ambiguous. In this depth-critique article, we aimed to investigate all possibilities and represented a novel and applicable approach from the Medicinal Chemistry concepts.

Keywords: ADRDs, type 2 diabetes mellitus, human post-mortem, insulin resistance, Alzheimer, medicinal chemistry.

[1]
Vafajoo A, Rostami A, Parsa SF, et al. Multiplexed microarrays based on optically encoded microbeads. Biomed Microdevices 2018; 20(3): 66.
[2]
Rabiee N. Micro-nano vehicles: Self-propelling approach toward the Future. OAT 2018.
[http://dx.doi.org/ DOI: 10.15761/FDCCR.1000105.]
[3]
Rabiee N. Metallodrugs: Medicinal chemistry investigation. OAT 2018.
[http://dx.doi.org/ DOI: 10.15761/FDCCR.1000104]
[4]
Vafajoo A, Rostami A, Parsa SF, et al. Early diagnosis of disease using microbead array technology: A review. Anal Chim Acta 2018; 1032: 1-17.
[5]
Nasseri B, Soleimani N, Rabiee N, Kalbasi A, Karimi M, Hamblin MR. Point-of-care microfluidic devices for pathogen detection. Biosens Bioelectron 2018; 117: 112-28.
[6]
Ghasemi A, Rabiee N, Ahmadi S, et al. Optical assays based on colloidal inorganic nanoparticles. Analyst 2018; 143(14): 3249-83.
[7]
Ahmadi S, Rabiee N, Rabiee M. Application of aptamer-based hybrid molecules in early diagnosis and treatment of diabetes mellitus: from the concepts toward the future. Curr Diabetes Rev 2018.
[http://dx.doi.org/DOI:10.2174/1573399814666180607075550.] ; [Epub ahead of print]..
[8]
Ansari AM, Bhat KG, Dsa SS, Mahalingam S, Joseph N. Study of Insulin Resistance in Patients With β Thalassemia Major and Validity of Triglyceride Glucose (TYG) Index. J Pediatr Hematol Oncol 2018; 40(2): 128-31.
[9]
Deb A, Sambamoorthi U, Thornton JD, Schreurs B, Innes K. Direct medical expenditures associated with Alzheimer’s and related dementias (ADRD) in a nationally representative sample of older adults–an excess cost approach. Aging Ment Health 2018; 22(5): 619-24.
[10]
Maciejewski ML, Mi X, Sussman J, et al. Overtreatment and deintensification of diabetic therapy among medicare beneficiaries. J Gen Intern Med 2018; 33(1): 34-41.
[11]
Pruzin J, Nelson P, Abner E, Arvanitakis Z. Relationship of type 2 diabetes to human brain pathology. Neuropathol Appl Neurobiol 2018; 44(4): 347-62.
[12]
Ahmad RMAH. Thinking about brain insulin resistance. Diabetes Metab Syndr 2018; 12(6): 1091-4.
[13]
MA APC.Alzheimer’s disease and dementia impacted by diabetes. Optometry Times 2018; 10(5): 14.
[14]
Rivera-Mancía S, Trujillo J, Chaverri JP. Utility of curcumin for the treatment of diabetes mellitus: Evidence from preclinical and clinical studies. JNIM 2018; 14: 29-41.
[15]
Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care 2015; 38(4): 588-95.
[16]
Talan J. Medicare data show one in ten hospitalizations for alzheimer’s patients could have been avoided. Neurol Today 2016; 16(15): 1-31.
[17]
Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 2018; 14(3): 168.
[18]
Frölich L, Blum-Degen D, Bernstein H-G, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm 1998; 105(4-5): 423-38.
[19]
Steen E, Terry BMJ, Rivera E, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63-80.
[20]
Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8(3): 247-68.
[21]
de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 2005; 7(1): 45-61.
[22]
Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimers Dement 2015; 11(6): 710-7.
[23]
Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003-2013: a decade of body mass index, Alzheimer’s disease, and dementia. J Alzheimers Dis 2015; 43(3): 739-55.
[24]
Cheng H, Wang L, Shi T, Shang Y, Jiang L. Association of insulin degrading enzyme gene polymorphisms with Alzheimer’s disease: a meta-analysis. Int J Neurosci 2015; 125(5): 328-35.
[25]
Arnoldussen IA, Sundh V, Bäckman K, et al. A 10-year follow-up of adiposity and dementia in swedish adults aged 70 years and older. J Alzheimers Dis 2018. (Preprint): 1-11.
[26]
Pistollato F, Ohayon EL, Lam A, et al. Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget 2016; 7(26): 38999.
[27]
Baudrand R, Pojoga LH, Vaidya A, et al. Statin use and adrenal aldosterone production in hypertensive and diabetic subjects. Circulation 2015; 132(19): 1825-33.
[28]
Mittermayer F, Caveney E, De Oliveira C, et al. Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development. Curr Diabetes Rev 2015; 11(1): 17-31.
[29]
Depetris RS, Hu J, Gimpelevich I, Holt LJ, Daly RJ, Hubbard SR. Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Molecular Cell 2005; 20(2): 325-33.
[30]
Song R, Peng W, Zhang Y, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 2013; 494(7437): 375.
[31]
Bettaieb A, Prieto MAV, Lanzi CR, et al. (−)-Epicatechin mitigates high-fructose-associated insulin resistance by modulating redox signaling and endoplasmic reticulum stress. Free Radic Biol Med 2014; 72: 247-56.
[32]
Prajapati B, Kumar Jena P, Rajput P, Purandhar K, Seshadri S. Understanding and modulating the Toll like Receptors (TLRs) and NOD like Receptors (NLRs) cross talk in type 2 diabetes. Curr Diabetes Rev 2014; 10(3): 190-200.
[33]
Niwas Jangir R, Chand Jain G. Diabetes mellitus induced impairment of male reproductive functions: a review. Curr Diabetes Rev 2014; 10(3): 147-57.
[34]
Copps KD, Hançer NJ, Qiu W, White MF. Serine 302 phosphorylation of mouse insulin receptor substrate 1 (IRS1) is dispensable for normal insulin signaling and feedback regulation by hepatic S6 kinase. J Biol Chem 2016; 291(16): 8602-17.
[35]
Sajan M, Hansen B, Ivey R, et al. Brain insulin signaling is increased in insulin-resistant states and decreases in FoxOs and PGC-1α and increases in Aβ1-40.42 and Phospho-Tau may abet alzheimer development. Diabetes 2016; 65(7): 1892-903.
[36]
De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014; 63(7): 2262-72.
[37]
Talbot K, Wang H-Y, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122(4): 1316-38.
[38]
M de la Monte S. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 2012; 9(1): 35-66.
[39]
De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer’s disease? Alzheimers Dement 2014; 10(1): S26-32.
[40]
Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007; 4(2): 147-52.
[41]
Suzanne M. Insulin resistance and Alzheimer’s disease. BMB Rep 2009; 42(8): 475.
[42]
Craft S, Rhoads K. Insulin resistance syndrome and Alzheimer’s disease Insulin Resistance Syndrome and Neuropsychiatric Disease. CRC Press 2016; pp. 104-18.
[43]
Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3(3): 169-78.
[44]
Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014; 63(7): 2253-61.
[45]
Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011; 68(1): 51-7.
[46]
Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci 2004; 101(9): 3100-5.
[47]
Bingham EM, Hopkins D, Smith D, et al. The role of insulin in human brain glucose metabolism: An 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002; 51(12): 3384-90.
[48]
Abolhassani N, Leon J, Sheng Z, et al. Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer’s disease brain. Mech Ageing Dev 2017; 161: 95-104.
[49]
Neth BJ, Craft S. Insulin resistance and Alzheimer’s disease: bioenergetic linkages. Front Aging Neurosci 2017; 9: 345.
[50]
Folch J, Ettcheto M, Busquets O, et al. The implication of the brain insulin receptor in late onset alzheimer’s disease dementia. Pharmaceuticals 2018; 11(1): 11.
[51]
Pomytkin I, Costa‐Nunes JP, Kasatkin V, et al. Insulin receptor in the brain: Mechanisms of activation and the role in the CNS pathology and treatment. CNS Neurosci Ther 2018; 24(9): 763-74.
[52]
Pardeshi R, Bolshette N, Gadhave K, et al. Insulin signaling: An opportunistic target to minify the risk of Alzheimer’s disease. Psychoneuroendocrinol 2017; 83: 159-71.
[53]
Kaushal S, Chopra S, Arora S. Molecules of the millennium-exenatide: An incretin-mimetic agent. Indian J Pharmacol 2008; 38(1): 76-8.
[54]
Bedell SE. Safe medication use in the older adult. Arch Intern Med 2000; 160: 2129-34.
[55]
Li H, Ren Y, Mao K, et al. FTO is involved in Alzheimer’s disease by targeting TSC1-mTOR-Tau signaling. Biochem Biophys Res Commun 2018; 498(1): 234-9.
[56]
Takeda S, Morishita R. Diabetes and Alzheimer’s disease Diabetes and aging-related complications. Springer 2018; pp. 101-11.
[57]
Denver P, English A, McClean PL. Inflammation, insulin signaling and cognitive function in aged APP/PS1 mice. Brain Behav Immun 2018; 70: 423-34.
[58]
Lee JH, Jahrling JB, Denner L, Dineley KT. Targeting insulin for alzheimer’s disease: Mechanisms, status and potential directions J Alzheimer Dis 2018(Preprint): ; 1-27.
[59]
Vignini A, Giulietti A, Nanetti L, et al. Alzheimer’s disease and diabetes: new insights and unifying therapies. Curr Diabetes Rev 2013; 9(3): 218-27.
[60]
Nicolls MR. The clinical and biological relationship between Type II diabetes mellitus and Alzheimer’s disease. Curr Alzheimer Res 2004; 1(1): 47-54.
[61]
McClean PL, Gault VA, Harriott P, Hölscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer’s disease. Eur J Pharmacol 2010; 630(1-3): 158-62.
[62]
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87(4): 1409-39.
[63]
Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 2004; 4(6): 589-96.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 4
Year: 2019
Page: [255 - 258]
Pages: 4
DOI: 10.2174/1573399814666181031154817

Article Metrics

PDF: 17
HTML: 2
EPUB: 1
PRC: 1